Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Rare Diseases

Melanoma

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Neuroendocrine Tumor

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Nivolumab

Antibodies

Antibodies, Monoclonal

Immunomodulating Agents

Immunoglobulins

Antibodies, Blocking

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Non-small cell lung cancer (NSCLC) or metastatic melanoma

APX005M 0.03 mg/kg and nivolumab 360 mg every 3 weeks

Non-small cell lung cancer (NSCLC) or metastatic melanoma

APX005M 0.1 mg/kg and nivolumab 360 mg every 3 weeks

Non-small cell lung cancer (NSCLC) or metastatic melanoma

APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks

Immunotherapy naïve, metastatic or locally advanced NSCLC

APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks

Metastatic melanoma progressing during treatment with anti-PD-1/PD-L1 therapy

APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks

Metastatic or locally advanced NSCLC progressing during treatment with anti-PD-1/PD-L1:

* Group A: best response of progressive disease or with stable disease \< 16 weeks
* Group B: tumor response or with stable disease ≥ 16 weeks

APX005M is a CD40 agonistic monoclonal antibody

APX005M

Nivolumab is an immune checkpoint (PD-1) blocking antibody

Medical Director

This study is a Phase 1-2 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M administered in combination with nivolumab to adult subjects with non-small cell lung cancer or metastatic melanoma. The Phase 1 portion is intended to establish the maximum tolerated dose and the recommended phase 2 dose of APX005M when administered in combination with nivolumab. The Phase 2 portion of the study will evaluate safety and efficacy of the combination.

APX005M-002 is an open-label Phase 1-2 study and comprises a dose-escalation portion (Phase 1) followed by a Phase 2 tumor specific portion.

Eligible subjects with non-small cell lung cancer or metastatic melanoma will receive intravenous APX005M in combination with nivolumab until disease progression, unacceptable toxicity or death, whichever occurs first.

Study objectives include:

* Determine the maximum tolerated dose and the recommended phase 2 dose of APX005M when given in combination with nivolumab
* Evaluate safety of the APX005M and nivolumab combination
* Evaluate the objective response rate, duration of response and median PFS by RECIST 1.1 in subjects with non-small cell lung cancer or metastatic melanoma receiving APX005M in combination with nivolumab
* Determine the PK of APX005M

Phase 1b dose escalation with up to 4 sequential dose levels. Followed by Phase 2 dose expansion at Recommended Phase 2 Dose in 3 parallel disease cohorts.

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination With Nivolumab in Subjects With Non-small Cell Lung Cancer and Subjects With Metastatic Melanoma

All toxicities were graded according to the NCI-CTCAE version 4.03. DLT was defined as any of the following events attributed to APX005M and nivolumab combination:

* Grade 4 hematologic toxicity lasting ≥ 7 days (except asymptomatic lymphopenia)
* Grade 3 or 4 neutropenia with a single temperature of \>38.3◦ C (101◦ F) or a sustained temperature of ≥38◦ C (100.4◦ F) for more than one hour
* Grade 4 thrombocytopenia or Grade ≥3 thrombocytopenia with signs or symptoms of bleeding or requiring platelet transfusion
* Grade 4 non-hematologic toxicity
* Grade 3 non-hematologic toxicity lasting \>3 days despite optimal supportive care
* Any Grade ≥ 3 non-hematologic laboratory value if: medical intervention is required to treat the subject, abnormality leads to hospitalization, or abnormality persists for \>1 week
* Failure to recover from a treatment-related AE to baseline or ≤ Grade 1 within 12 weeks of last dose of investigational product
* Grade 5 toxicity.

Establish the MTD dose of APX005M combined with 360 mg of nivolumab for which for which \< 33% of DLT- evaluable participants experience a DLT. In Phase 1b, the RP2D was based on the overall safety and tolerability of the combination of APX005M and nivolumab by testing increasing doses up to 0.3 mg/kg APX005M + nivolumab.

ORR defined as the rate of patients who show as best overall response; either a complete response (CR) or a partial response (PR). The ORR can be evaluated by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. using computed tomography (CT) scans/magnetic resonance imaging (MRI). Per RECIST v1.1, for target lesions and assessed by imaging: Complete Response, (CR), Disappearance of all target lesions and nontarget (NT) lesions; Partial Response (PR), \>30% decrease in the sum of the longest diameter of target lesions and no PD in NT lesions or new lesions; Objective Response Rate (ORR)=CR + PR.

Number of participants with TEAEs are reported.

Duration of Response is defined as the time from the first evidence of confirmed partial response (PR) or better by Per RECIST v1.1 to disease progression or death due to any cause; in subjects alive without progressive disease (PD), DOR was censored on the date of the last tumor assessment. PD is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Progression-free Survival (PFS) in each cohort, measured from first dose to the earlier of PD (by RECIST 1.1) or death due to any cause, whichever occurs first.

PFS rate in each cohort, measured from first dose to the earlier of PD (by RECIST 1.1) or death due to any cause, whichever occurs first.

Bristol-Myers Squibb

Apexigen America, Inc.

An AE considered "serious" (SAE) if, in the view of either the Investigator or sponsor, it results in any of the following outcomes:

* Death
* A life-threatening AE
* Inpatient hospitalization or prolongation of existing hospitalization
* A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
* A congenital anomaly/birth defect

Participants received 0.03 mg/kg of APX005M administered every 21 days in combination with nivolumab 360 mg IV

DL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b Escalation)

Participants received 0.1 mg/kg of APX005M administered every 21 days in combination with nivolumab 360 mg IV

DL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b Escalation)

Participants received 0.3 mg/kg of APX005M administered every 21 days in combination with nivolumab 360 mg IV

Note: One participant was rolled over to Cohort 1 (Phase 2) and 2 participants were rolled over into Cohort 2 (Phase 2).

DL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b Escalation)

Participants received 0.3 mg/kg of APX005M administered every 21 days in combination with nivolumab 360 mg IV

Cohort 1(Arm)/ inNSCLC (Phase 2) - Includes Data From 1 Participant From DL3

Cohort 2(Arm)/ PD1-MM (Phase 2) - Includes Data From 2 Participants From DL3

Cohort 3A(Arm)/ PD1-NSCLC (Phase 2)

Cohort 3B(Arm)/ PD1-NSCLC (Phase 2)

DL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b)

DL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b)

DL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b)

Cohort 1(Arm)/ inNSCLC (Phase 2)

Cohort 2(Arm)/ PD1-MM (Phase 2)

Total

Phase 1b Age, Categorical

Phase 2 Age, Categorical

The participants were enrolled into multiple Arms/Groups and are reported in the Arm/Group they were originally assigned.

Age, Categorical

Phase 1b

Phase 2

The participants were enrolled into multiple Arms/Groups and are reported in the Arm/Group they were originally assigned

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

United States

Spain

Region of Enrollment

Weight

Grade 0 - Normal activity, fully active, able to carry on all pre-disease performance without restriction Grade 1 - Symptoms, but fully ambulatory, restricted in physically strenuous but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work)

Grade 0 is better than Grade 1.

ECOG Performance Status

Phase 1b: immunotherapy naïve metastatic or locally advanced NSCLC (inNSCLC) or unresectable or metastatic melanoma (MM) Phase 2: Cohort 1/inNSCLC, Cohort 2/unresec or MM that progressed during treatment with anti-PD-1/PD-L1, Cohort 3/PD1-NSCLC metastatic or locally advanced NSCLC not amenable to curative treatment that progressed during prior treatment with anti-PD-1/PD-L1. Cohort 3A: best response of PD or with SD \<16 wks, Cohort 3B includes PD1-NSCLC with tumor response or with SD ≥ 16 wks.

In the AE section, DL3 participant data had no DLTs; AE data collected from DL3 was also added to Phase 2.

Pyxis Oncology Clinical Operations

Participants received intravenous infusions of APX005M starting at DL 0.03, .1 or .3 mg/kg administered every 21 days in combination with nivolumab 360 mg IV

Phase 1b Escalation

All participants in the safety population who received at least 1 dose of study drug in the escalation cohorts (APX005M 0.03 mg/kg + nivolumab; APX005M 0.1 mg/kg + nivolumab; APX005M 0.3 mg/kg + nivolumab)

Number of Participants Experiencing Dose-limiting Toxicities (DLTs)

Maximum Tolerated Dose (MTD) of APX005M + Nivolumab (Phase 1b)

Cohort 1 (Arm)/inNSCLC (Phase 2)

Cohort 2(Arm)/PD1-MM (Phase 2)

Cohort 3A(Arm)/PD1-NSCLC (Phase 2)

Cohort 3B(Arm)/PD1-NSCLC (Phase 2)

Cohort 1: immunotherapy naïve metastatic or locally advanced NSCLC, Cohort 2: unresectable or metastatic melanoma that progressed during treatment with anti-PD-1/PD-L1 therapy and had confirmation of PD ≥4 weeks, Cohort 3: PD1-NSCLC metastatic or locally advanced NSCLC not amenable to curative treatment that progressed during prior treatment with anti-PD-1/PD-L1 therapy. Cohort 3A: best response of PD or with SD \<16 weeks, Cohort 3B includes PD1-NSCLC with tumor response or with SD ≥ 16 weeks

Phase 2 Evaluate the Objective Response Rate (ORR) by RECIST 1.1 and iRECIST in Each Cohort / Group

Any Adverse Event a participant has with two or more events in that category is counted only once

Safety of the APX005M and Nivolumab Combination (Phase 2)

Cohort 1(Arm)/inNSCLC (Phase 2)

Cohort 1: immunotherapy naïve metastatic or locally advanced NSCLC, Cohort 2: unresectable or metastatic melanoma that progressed during treatment with anti-PD-1/PD-L1 therapy and had confirmation of PD ≥4 week. Cohort 3A/PD1-NSCLC and Cohort 3B/PD1 NSCLC had no objective response and therefore DOR could not be assessed.

Duration of Response (DOR) as Per RECIST 1.1(Phase 2)

Cohort 1: immunotherapy naïve metastatic or locally advanced NSCLC, Cohort 2: unresectable or metastatic melanoma that progressed during treatment with anti-PD-1/PD-L1 therapy and had confirmation of PD ≥4 weeks, Cohort 3: PD1-NSCLC metastatic or locally advanced NSCLC not amenable to curative treatment that progressed during prior treatment with anti-PD-1/PD-L1 therapy. Cohort 3A: best response of PD or with SD \<16 weeks, Cohort 3B includes PD1-NSCLC with tumor response or with SD ≥ 16 weeks.

Median Progression-free Survival (PFS) (Phase 2)

6-month PFS Rate (Phase 2)

Participants received 0.03mg/kg of APX005M administered every 21 days in combination with nivolumab 360 mg

Participants received 0.1mg/kg of APX005M administered every 21 days in combination with nivolumab 360 mg

Participants received 0.3 mg/kg of APX005M administered every 21 days in combination with nivolumab 360 mg

Cohort 2(Arm)/ PD1-MM (Phase 2) -

Digestive System Diseases

Esophageal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Head and Neck Neoplasms

Gastrointestinal Diseases

Esophageal Diseases

Esophageal Cancer

Complete an 8-week community based prehab program.

Prehabilitation

Jodi Langley

Research indicates that individuals diagnosed with lung or esophageal cancer who enter treatment with higher functional capacities, improved body composition, and better nutrition status tend to experience better outcomes and a higher quality of life. The primary objective of a prehabilitation health coaching program is to enhance the overall health and well-being of patients before they undergo major surgery.This personalized 8-week program encompasses elements such as nutrition, smoking cessation, sleep hygiene, and movement, equipping participants with the knowledge and tools needed to adopt healthier lifestyles.

The purpose of this study is to explore the implementation, feasibility and effectiveness of a community-based prehabilitation health coaching program, including nutrition, smoking cessation, sleep hygiene and movement for individuals scheduled to undergo surgery for lung or esophageal cancer.. Participants will have the option to engage in a one-on-one prehabilitation health coaching program tailored to their needs, led by a Qualified Exercise Professional (QEP). The personalized prehabilitation plan will encompass 4-6 in-person or virtual meetings before surgery, including a structured movement plan, education on smoking cessation, sleep quality, stress reduction, mindfulness, and nutrition. Post-surgery, the QEP will provide support through counselling and scheduled sessions for a month after surgery and include one session while the patient is in hospital.

This research adopts a repeated measure, mixed-methods approach. Participants will undergo three clinical assessments at different stages: baseline, pre-surgery, and 4-6 weeks post-surgery. The findings from this study will guide future grant applications aimed at funding larger studies and the implementation of prehabilitation as part of standard of care in lung and esophageal cancer patients in Nova Scotia.

Central to the research endeavor is the driving question: "How can a community-based prehabilitation program be successfully implemented in the community, and can it lead to improved functional outcomes in patients undergoing surgery for lung or esophageal cancer?" This overarching question provides the study with its core focus and serves as a guiding force throughout the research process.

Prehab for Lung and Esophageal Cancer

Prehab for Lung and Esophageal Cancer: Optimizing Well-being for Better Outcomes

Participant accrual as defined as the number of eligible participants who consent to participate

Participant adherence to prescribed exercise intervention

Percentage of participants who complete the 12-week intervention

Exit interview is used to assess factors influencing participant selection of intervention type/setting, adherence to and satisfaction with the health coaching program

Attendance is calculated as the percentage of exercise sessions completed by the total number of available exercise sessions over the 8-10-week intervention.

44 item that measures multidimensional quality of life

a 13-item questionnaire that evaluates an individual's self-reported fatigue during their usual daily activities over the past week

To test functional strengths, risk of falling and overall leg strength and endurance

To test functional strength, balance and agility

resting systolic and diastolic blood pressure

Dalhousie University

Nova Scotia Health Authority

Assistant Professor

Diagnostic bronchoscopy is done according to institutional practice with the addition of nCLE

Diagnostic bronchoscopy is done according to institutional practice without the addition of nCLE

Confocal microscopy through the TBNA needle before tissue sampling using the Cellvizio system and AQ flex probe (Mauna Kea Technologies)

Neelde Based Confocal Laser Endomicroscopy

Conventional diagnostic bronchoscopy with r-EBUS and optionally fluoroscopy AND/OR EMN AND/OR VB AND/OR ultrathin scope

Conventional diagnostic bronchoscopy

Saskia van Heumen, MSc

Jouke Annema, Prof. dr.

Ali Sadoughi, MD, DAABIP

Daniela Gompelmann, Prof.

Daniela Gompelmann

Christina Bal

Jirí Votruba

Zuzana Šestáková

Grigoris Stratakos, MD, PhD

Nektarios Anagnostopoulos

Evangelia Koukaki

Grigoris Stratakos

Katerina Bakiri

Venerino Poletti, Prof.

Claudia Ravaglia

Venerino Poletti, MD, PhD

Jouke Annema

Saskia van Heumen

Peter Bonta

Johannes Daniels

Marjolein Heuvelmans

Jürgen Hetzel, Prof.

Jürgen Hetzel

Maik Haentschel

The goal of this multi-center randomized clinical trial is to evaluate the added value of needle based confocal laser endomicroscopy (nCLE)-imaging to regular diagnostic bronchoscopic peripheral lung lesion analysis on the diagnostic yield in patients with peripheral pulmonary nodules suspect for malignancy.

The main question\[s\] it aims to answer are:

To determine if the addition of nCLE-imaging to conventional diagnostic bronchoscopic peripheral lung lesion analysis results in an improved diagnostic yield (defined as the proportion of patients in whom the bronchoscopic procedure results in a definitive diagnosis out of the total number of patients that have received the diagnostic bronchoscopic procedure).

Participants will undergo diagnostic bronchoscopy either with or without the addition of nCLE imaging before each TBNA. Based on the feedback of the CLE images on (in)correct placement of the needle, the needle might be repositioned before sampling. Comparison between the diagnostic yield of these groups will be done including subgroup analysis.

Rationale: Lung cancer screening and the increasing use of chest-computed tomography (CT) has led to an increase in the number of (incidental) found suspected malignant lung lesions. Since tissue acquisition for pathological analysis is prerequisite for diagnosis and optimal treatment, a drastic increase in the number of patients that need to undergo bronchoscopy is expected.

Over 70% of the suspected lesions develop in the periphery of the lung and are therefore not visible during conventional bronchoscopy. Although several bronchoscopic navigational techniques demonstrated an improved navigation towards the target lesion, the diagnostic yield remains suboptimal due to a substantial near-miss rate. As a result, the need for complementary bronchoscopic guidance that provides real-time feedback on the correct positioning of the biopsy instruments is urgent.

Needle-based Confocal laser endomicroscopy (nCLE) is a novel high-resolution imaging technique that uses an excitation laser light to create 'real-time' microscopic images of tissues. nCLE can be integrated into the biopsy needle, allowing real-time cancer detection at the tip of the biopsy needle during bronchoscopy. The confocal microscope captures autofluorescence of tissues or, combined with intravenously (IV) infused fluorophores (such as fluorescein) allows imaging of individual tumor cells. Recent studies on nCLE-imaging in lung tumors and metastatic lymph nodes have identified and validated nCLE criteria for malignancy (enlarged pleomorphic cells, dark clumps and directional streaming) and airway/lung parenchyma (alveoli, elastin fibres of the conducting airway, bronchial epithelium and still image) and granulomas. A recent study demonstrated that these nCLE-criteria can be used in real-time to fine-tune the needle positioning during ongoing bronchoscopy and thereby potentially improve the diagnostic yield.

This randomized controlled trials aims to evaluate the added value of nCLE-imaging (smart needle) to the conventional used bronchoscopic approach for peripheral lung lesion analysis.

Objective: This multicenter, randomized controlled trial, aims to investigate if nCLE-imaging integrated with conventional bronchoscopy results in a higher diagnostic yield compared to conventional bronchoscopy without nCLE in the diagnosis of peripheral lung nodules.

Study design: Investigator-initiated, international, multi-center randomized controlled trial including university and general hospitals.

Study population: Patients (\>18 years old) with suspected malignant peripheral lung lesions with an indication for bronchoscopic analysis.

Procedure: Bronchoscopy will be performed according to institutional practice, including radial endobronchial ultrasound (r-EBUS) and optionally fluoroscopy, electromagnetic navigation, virtual bronchoscopy and/or ultrathin bronchoscopy. This is followed by transbronchial needle aspiration (TBNA) and (cryo-)biopsies (control arm). In the study arm, nCLE-imaging will be added prior to TBNA tissue acquisition to fine-tune the sampling area. Cytology staining for rapid onsite evaluation (ROSE) and cellblock will be performed according to local practice.

Primary objective:

To determine if the addition of nCLE-imaging to conventional bronchoscopic peripheral lung lesion analysis results in an improved diagnostic yield. (defined as the proportion of patients in whom the bronchoscopic procedure results in a definitive diagnosis out of the total number of patients that have received the diagnostic bronchoscopic procedure).

Confocal Laser Endomicroscopy VERification

Bronchoscopy With and Without Needle-based Confocal Laser Endomicroscopy for Peripheral Lung Nodule Diagnosis: Protocol for a Multicenter Randomized Controlled Trial (CLEVER Trial)

All data relevant to the study will be included in the article or uploaded as supplementary information. Data requests can be submitted to the researchers at the Amsterdam UMC, Amsterdam, The Netherlands.

Diagnostic yield (defined as the proportion of patients in whom the bronchoscopic procedure results in a definitive diagnosis \[either malignant, specific benign or non-specific benign confirmed as benign in follow-up\], relative to the total number of patients that underwent the diagnostic bronchoscopic procedure). If patients with multiple lesions are included, the diagnostic yield will be computed per nodule.

Diagnostic sensitivity for malignancy (defined as the proportion of patients in whom the bronchoscopic procedure diagnoses malignancy relative to the total number of patients with a final diagnosis of malignancy as determined by the reference standard).

Diagnostic yield according to the strict definition by Vachani et al.(21) (defined as the proportion of patients in whom the bronchoscopic procedure results in a definitive diagnosis \[either malignant or specific benign diagnosis\], relative to the total number of patients that underwent the diagnostic bronchoscopic procedure).

Procedure duration (from bronchoscope insertion until removal).

Percentage of patients in which the needle was fine-tuned (defined as moving the needle within the same distal airway) or repositioned (defined as the selection of a different distal airway for tissue sampling) based on nCLE feedback (defined as the number of patients the needle was fine-tuned/repositioned divided by the total number of patients in which nCLE imaging was used).

Diagnostic yield of ROSE (defined as the proportion of patients in whom ROSE resulted in a classifying diagnosis \[malignant or specific benign diagnosis\], relative to the total number of patients).

Proportion of patients in which ROSE provided tool-in-lesion confirmation, meaning that the acquired tissue shows signs of a malignant or non-malignant diagnosis and was not related to airway/lung parenchyma sampling such as bronchus epithelium/blood contamination, and tissue not suitable for a specific diagnosis such as atypical cells.

Complication rate (defined as any complication or complication categories occurring during or directly after the bronchoscopic procedure or any procedure-related complication within one week after the procedure).

Requirement of additional diagnostic procedures (CT-guided transthoracic biopsies, surgical diagnostics and/or additional bronchoscopy) during the 6-month follow-up period.

To assess the diagnostic yield (primary outcome) for two subgroups (≤20 mm vs \>20 mm)

To assess the diagnostic yield (primary outcome) for three subgroups (eccentric vs concentric vs absent)

To assess the diagnostic yield (primary outcome) for three subgroups (upper lobe (without lingual) vs middle lobe/lingual vs lower lobe)

To assess the diagnostic yield (primary outcome) for three subgroups (Brock score \<10%, 10 - 35%, 36-70% and \>70%)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab	NCT03123783	Cancer Non Small Cell ... Metastatic Mela... Neoplasm of Lun... Melanoma	APX005M Nivolumab	18 Years -	Apexigen America, Inc.
Prehab for Lung and Esophageal Cancer	NCT06354959	Neoplasm of Lun... Neoplasms Exercise Surgery	Prehabilitation	18 Years -	Nova Scotia Health Authority
Confocal Laser Endomicroscopy VERification	NCT06079970	Lung Cancer Lung Neoplasm M... Carcinoma, Non-... Neoplasm of Lun...	Neelde Based Co... Conventional di...	18 Years -	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab	NCT03123783	Cancer Non Small Cell ... Metastatic Mela... Neoplasm of Lun... Melanoma	APX005M Nivolumab	18 Years -	Apexigen America, Inc.
Confocal Laser Endomicroscopy VERification	NCT06079970	Lung Cancer Lung Neoplasm M... Carcinoma, Non-... Neoplasm of Lun...	Neelde Based Co... Conventional di...	18 Years -	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Effect of Incidental Findings Information on Lung Cancer Screening Intent	NCT04432753	Neoplasm of Lun... Decision Suppor... Mass Screening	Lung Cancer Scr... Lung Cancer Scr...	55 Years - 80 Years	UNC Lineberger Comprehensive Cancer Center
Postoperative Analgesia With a Catheter Under the Erector Spinae Muscle for Videothoracoscopic Lung Surgery	NCT04665531	Neoplasm of Lun... Thoracic Surger...	Erector Spinae ... Intercostal blo... Ropivacaine 0.2...	18 Years -	Surgery Bitenc
9-ING-41 in Patients With Advanced Cancers	NCT03678883	Cancer Pancreatic Canc... Sarcoma Renal Cancer Refractory Canc... Refractory Neop... Refractory Non-... Pancreatic Aden... Resistant Cance... Neoplasm Metast... Neoplasm of Bon... Neoplasm, Breas... Neoplasm of Lun... Neoplasms,Color... Neoplasms Pancr... Malignant Gliom... Malignancies Malignancies Mu... Bone Metastases Bone Neoplasm Bone Cancer Pancreas Cancer Pancreatic Neop... Breast Neoplasm... Acute T Cell Le...	9-ING-41 Gemcitabine - 2... Doxorubicin. Lomustine Carboplatin. Nab paclitaxel. Paclitaxel. Gemcitabine - 2... Irinotecan	18 Years -	Actuate Therapeutics Inc.
Efficacy of Continous Regional Anesthesia Using m. Erector Spinae Catheter After VATS Procedures	NCT04062045	Neoplasm of Lun... Thoracic Surger...	Ropivacaine Hcl... Saline 0.9%	18 Years -	Surgery Bitenc

Spots Global Cancer Trial Database for neoplasm of lung